GlassScriptPhysician profile
Sandy Dorival
NPI 1689309510
$530.28
in general payments reported to CMS, 2019-2025
11 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.94 · 2023: $239 · 2024: $32.79 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $163.67 | 2025 | Synchromedii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.03 | 2023 | Xifaxan, Trulance |
| Novocure INC. | $53.21 | 2024-2025 | Optune, Optune Lua (Novottf-200t) |
| Novo Nordisk INC | $51.61 | 2022-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $48.68 | 2023 | |
| Novartis Pharmaceuticals Corporation | $37.88 | 2022 | |
| Pfizer INC. | $25.83 | 2023 | |
| Idorsia Pharmaceuticals US INC | $20.69 | 2023 | Quviviq |
| Abbvie INC. | $18.11 | 2023 | |
| Blue Earth Diagnostics | $17.24 | 2025 | Posluma |
| Glaxosmithkline, LLC. | $14.33 | 2023 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Dorival listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.